Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Instagram Outage Disrupts Thousands of U.S. Users 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
PARSIPPANY, N.J., June 01, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Jefferies 2017 Global Healthcare Conference at 1:30 PM ET on Tuesday, June 6, 2017 in New York City.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
